中银国际发表研究报告指，药明康德上半年业绩表现强劲，收入及净利润增长稳健，利润率扩张，TIDES业务表现突出，化学业务韧性增长。管理层上调2025年收入指引至介乎425亿至435亿元，即持续经营业务料增长13%至17%，资本开支维持70亿至80亿元不变。中银国际将药明康德今明两年盈利预测上调15%及22%，目标价从81港元上调至122港元，维持“买入”评级。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.